30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

Abstract

SummaryBackground30-day mortality might be a useful indicator of avoidable harm to patients from systemic anticancer treatments, but data for this indicator are limited. The Systemic Anti-Cancer Therapy (SACT) dataset collated by Public Health England allows the assessment of factors affecting 30-day mortality in a national patient population. The aim of this first study based on the SACT dataset was to establish national 30-day mortality benchmarks for breast and lung cancer patients receiving SACT in England, and to start to identify where patient care could be improved.MethodsIn this population-based study, we included all women with breast cancer and all men and women with lung cancer residing in England, who were 24 years or older and who started a cycle of SACT in 2014 irrespective of the number of previous treatment cycles or programmes, and irrespective of their position within the disease trajectory. We calculated 30-day mortality after the most recent cycle of SACT for those patients. We did logistic regression analyses, adjusting for relevant factors, to examine whether patient, tumour, or treatment-related factors were associated with the risk of 30-day mortality. For each cancer type and intent, we calculated 30-day mortality rates and patient volume at the hospital trust level, and contrasted these in a funnel plot.FindingsBetween Jan 1, and Dec, 31, 2014, we included 23 228 patients with breast cancer and 9634 patients with non-small cell lung cancer (NSCLC) in our regression and trust-level analyses. 30-day mortality increased with age for both patients with breast cancer and patients with NSCLC treated with curative intent, and decreased with age for patients receiving palliative SACT (breast curative: odds ratio [OR] 1·085, 99% CI 1·040–1·132; p<0·0001; NSCLC curative: 1·045, 1·013–1·079; p=0·00033; breast palliative: 0·987, 0·977–0·996; p=0·00034; NSCLC palliative: 0·987, 0·976–0·998; p=0·0015). 30-day mortality was also significantly higher for patients receiving their first reported curative or palliative SACT versus those who received SACT previously (breast palliative: OR 2·326 99% CI 1·634–3·312; p<0·0001; NSCLC curative: 3·371, 1·554–7·316; p<0·0001; NSCLC palliative: 2·667, 2·109–3·373; p<0·0001), and for patients with worse general wellbeing (performance status 2–4) versus those who were generally well (breast curative: 6·057, 1·333–27·513; p=0·0021; breast palliative: 6·241, 4·180–9·319; p<0·0001; NSCLC palliative: 3·384, 2·276–5·032; p<0·0001). We identified trusts with mortality rates in excess of the 95% control limits; this included seven for curative breast cancer, four for palliative breast cancer, five for curative NSCLC, and seven for palliative NSCLC.InterpretationOur findings show that several factors affect the risk of early mortality of breast and lung cancer patients in England and that some groups are at a substantially increased risk of 30-day mortality. The identification of hospitals with significantly higher 30-day mortality rates should promote review of clinical dec...

Thirty‐day mortality after systemic anticancer treatment as a real‐world, quality‐of‐care indicator: the Northland experience

“…Our audit demonstrated the feasibility of 30‐day mortality as an indicator for accessing quality in real‐life practice in a regional outpatient oncology unit in New Zealand. This study is unique as it audited 30‐day mortality over 5 years, as opposed to other contemporary studies, which chose shorter time frames (6–18 months) …”

Gut microbiota modulation of chemotherapy efficacy and toxicity

“…Cytotoxic drugs continue to be the mainstay of medical treatment for most patients with advanced disease, yet they have an unpredictable treatment response and considerable treatment-related morbidity and mortality 2 . The next generation of personalized cancer therapies are now emerging 3 , which exploit advances in molecular and phenotypic heterogeneity 4,5 , tumour evolution, immunotherapy and vaccination.…”

Cancer drugs, survival, and ethics

“…29 There is also a drug and disease dependent risk of death from treatment itself, especially in the first month of therapy. 30 Nor are patients likely to be informed of the increased risk of dying in hospital compared with patients receiving only supportive care. 31 This is important, since studies show that most patients prefer to end their lives in their own homes or hospices rather than in hospital.…”